- Going to BPI West 2017? Don’t miss these great talks and activities!Posted 18 hours ago
- Cool Tool – PRIME-XV® T Cell CDM – First Commercially Available Chemically-defined, Animal-component-free Medium for T Cell CulturePosted 3 days ago
- Increasing Protein Production with Novel Cell-Ess Titer Boost without Affecting the Metabolic ProfilePosted 1 week ago
- Continuous Processing Optimization with Smarter ToolsPosted 1 week ago
- Cool Tool – Generation of Neural Stem Cells from AlphaSTEM Cultured Pluripotent Stem CellsPosted 1 week ago
- Synergizing Transient and Stable Protein Expression for Accelerated Biotherapeutic DevelopmentPosted 2 weeks ago
- Cell Culture Dish Top Ten Ask the Expert Sessions and Podcasts of 2016Posted 2 weeks ago
- A Look at the Current State of Continuous BioprocessingPosted 2 weeks ago
- Cool Tool – Biomek i-Series – Next Generation Automated Workstations Specifically Designed to Meet Evolving WorkflowsPosted 3 weeks ago
- Filling Industry Gaps with Dedicated Cell Therapy Fluid Transfer SetsPosted 3 weeks ago
The Dish’s Weekly Biotechnology News Wrap Up – January 22, 2016
This week’s biotechnology news headlines include, Merck to submit ebola vaccine for approval, information about Zika virus, Samsung’s Enbrel biosimilar approved in EU, Pluristem gets FDA approval for Phase I study, finding the gems in DNA, Pfizer deciding on equipment sales and Acorda acquires Biotie Therapies.
Cell Culture Events
Wednesday, January 27, 2016
USA 12:00 Noon EST / 9:00 AM PST
Europe 11:00 AM CET / 10:00 AM London (GMT)
Asia 2:00 PM Seoul/ 1:00 PM Singapore (SGT)/ 10:30 AM India
Australia 4:00 PM Sydney (AEDT)
About this webinar:
Human mesenchymal stem cells (hMSCs) are currently the subject of many clinical trials world-wide, as researchers develop new treatments for a variety of regenerative and inflammatory diseases. The use of a completely defined, serum-free, xeno-free culture system for hMSCs is necessary to provide control over research variables and reduce the inconsistency inherent in serum-containing culture systems.
David Fiorentini will provide an overview of the novel NutriStem® MSC xeno-free, serum-free culture system, which efficiently supports initial isolation and optimal expansion of hMSCs from a variety of sources, while maintaining appropriate hMSC features, such as proper fibroblast-like cell morphology, phenotypic surface marker expression profiles, differentiation capacity, self-renewal potential, and genetic stability over time. In addition, he will also describe the MSCgo™ family of xeno-free, serum-free differentiation media for use in generating mature adipocytes, osteoblasts, and chondrocytes using hMSCs isolated from a variety of sources.
Who Should Attend?
- Any researcher culturing hMSCs isolated from bone marrow, adipose tissue, cord blood, Wharton’s Jelly, placental tissue, or other source
- Researchers interested in improving cell culture results and minimizing lot-to-lot variation between experiments
- Researchers interested in learning new techniques for isolation, culture, cryopreservation, and/or differentiation of hMSCs
- Researchers interested in working with xeno-free and/or clinical grade hMSC culture conditions
Register here – http://www.bioind.com/msc-webinar
PepTalk – January 18-22, 2016 – San Diego, CA
PepTalk: The Protein Science Week is one of the largest gatherings of protein science researchers in the world. It offers an array of education, innovation and networking programs, and provides many opportunities to scientists.
Tuesday, January 19th at 9:35
Hollow Fiber Perfusion Bioreactors; The Original Upstream Single Use Continuous Manufacturing Technology
Scott Waniger, Vice President, Bioservices, Cell Culture Company
Hollow fiber perfusion bioreactor technology has been used in the bioprocessing industry for 30+ years and continues to be used to manufacture regulated biologics worldwide. While the technology has many similarities to stirred tank bioreactors, it also offers significant advantages over traditional technologies for many applications. The presentation will describe these advantages while explaining the setup, daily operation, and turn-around of this accepted technology within the bioprocessing industry. A case study showing steady state production of a monoclonal antibody (IgG) using hollow fiber bioreactors will be included.
SLAS (Society for Laboratory Automation and Screening) – January 23-27, 2016 – San Diego, CA
If you are attending SLAS this year, don’t miss these exciting events – http://info.beckmancoulter.com/l/60792/2016-01-11/6bfw7b
Cell Therapy Manufacturing – February 3-4, 2016– Brussels, Belgium
Cell Culture World Congress – February 23-24, 2016 –Munich Germany
The Cell Culture World Congress is where pharma, biotechs, researchers & innovative start-ups gather to develop new strategies and partnerships to advance biotherapeutic production, manufacture, and commercialisation. Join the largest cell culture event focused on producing new therapeutics and immunotherapies at a commercial scale and see where biologic manufacture is headed next.
Key speakers include:
Dr Stefan Wildt, VP, Global Head Technical Research and Development, Cell- and Gene Therapies, Novartis.
Bo Kara, Head Process Development, Advanced Therapy Delivery, GSK
Sam Wadsworth, CSO, Dimension Therapeutics
Dr Lorenz Mayr Vice President of Reagents & Assay Development at AstraZeneca
For more information download the brochure: http://bit.ly/1JJWO5y
Downstream Processing World Congress – February 23-24, 2016 – Munich Germany
The Downstream Processing World Congress 2016 will introduce new and exciting content focusing on innovation and development with an emphasis on new methods. Showcasing exciting new technologies such as purifying complex molecules, PAT, continuous purification, chromatography alternatives and new methods of purification. Content will include cutting edge research and even more case studies , over 40 presentations from those working in bioprocess in big pharma, interactive sessions with biotechs and will be collocated with the 6th annual Cell Culture World Congress.
Key speakers include:
Dr Mark Federspiel, Director, Viral Vector Production Laboratory, Department of Molecular Medicine, Mayo Clinic
Dr Yogesh Waghmare, Staff Scientist, Late Stage Process Development, Genzyme Sanofi
Nicholas Clarkson, Group Lead, Analytical Development, Oxford Biomedica
Prof Manuel Carrondo, Director, IBET
For more information download the brochure: http://bit.ly/1l5kQMx
ISBioTech 6th Spring Meeting – March 7-9, 2016 -Washington, DC
Three concurrent programs on:
– Cellular Therapies
– Viral Vectors & Vaccines
– Baculovirus Expression Technology
BPI West – March 14-March 17, 2015 – Oakland Marriott City Center, Oakland, CA
World Vaccine Congress – March 29-30, 2016 –Grand Hyatt– Washington D.C.
Check out the Top Blogs, Top Ask the Expert Sessions and Top Cool Tool Features of 2015 –
“Merck & Co. has signed an agreement with Gavi, the world’s biggest funder of vaccines for developing countries, to submit its experimental Ebola vaccine for regulatory approval by the end of 2017.”
If you like this story, please see our blog titled “Biomanufacturing CHO Media – A look at different approaches and optimization opportunities”
“The Centers for Disease Control and Prevention has warned pregnant women against travel to several countries in the Caribbean and Latin America where the Zika virus is spreading. Infection with the virus appears to be linked to the development of unusually small heads and brain damage in newborns. Some pregnant women who have been to these regions should be tested for the infection, the agency also says. Here are some answers and advice about the outbreak.”
If you like this story, please see our blog titled “Cool Tool – Gibco Essential 8 Flex Stem Cell Media Eliminates Need for Daily Feeding”
“Samsung Bioepis Co Ltd said on Sunday it had received European Commission approval for its copy of the blockbuster biotech arthritis drug Enbrel.”
If you like this story, please see our blog titled “Biomanufacturing Innovations are Plentiful at This Year’s BPI Conference”
“Pluristem Therapeutics Inc. announced that the FDA has cleared its Investigational New Drug (IND) application to begin a phase I trial on PLX-R18 cells for treating incomplete hematopoietic recovery following hematopoietic cell transplantation (HCT).”
If you like this story, please see our blog titled “Cool Tool- Hybridoma cell growth and performance in reduced serum + Zap-SR”
“When you learned about genes in high school, chances are it went something like this: Our DNA holds about 20,000 protein-coding genes. To make a protein, a cell makes a copy of the corresponding gene, in the form of a single-stranded molecule called RNA. The cell uses the RNA molecule as a template to make the protein. And then the protein floats off to do its job.”
If you like this story, please see our blog titled “Another Perspective on 4D Bioprinting”
“Pfizer Inc. is weighing a sale of the pumps and devices business it acquired in last year’s purchase of Hospira Inc., people with knowledge of the matter said.”
If you like this story, please see our blog titled “Hollow Fiber Provides a Sweet Spot for Several Biomanufacturing Applications”
“Acorda Therapeutics is snapping up Finnish biotech Biotie Therapies in a deal valued at around $363 million, giving the firm a much stronger footprint in the Parkinson’s disease field.”
If you like this story, please see our blog titled “You can teach an old dog new tricks: Vero cells for virus-based cancer vaccine therapies”